CEPMED is a non-profit organization dedicated to promoting the science and practice of personalized medicine through research, commercialization and education. It currently participates in several multi-million dollar public-private partnerships in translational medicine that incorporate pharmacogenetic testing into Phase III clinical trials and into studies of marketed products. In addition, it funds strategic personalized medicine research projects with high commercialization potential. In 2010, CEPMED will complete an in-depth physician survey on the state of personalized medicine adoption in Canada and launch a nation-wide education campaign. Founded by the Montreal Heart Institute, CEPMED makes use of the Beaulieu-Saucier Pharmacogenomics Centre, the Montreal Heart Institute Coordinating Centre and the Montreal Heart Institute Biobank in its projects. It is a Centre of Excellence for Commercialization and Research (CECR) and supported by the Canadian Government, Genome Quebec as well as private partners including Pfizer, AstraZeneca, Novartis and Merck.